MDGS - Medigus company Polyrizon to test its product candidate against Omicron variant

Medigus (MDGS +1.9%) announces that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, will evaluate the viral infection prophylaxis effect of its innovative product candidate against the Omicron variant of coronavirus, in-vitro. This study follows recent pre-clinical studies showed strong potential against human coronavirus 229E and influenza virus infection. Polyrizon is planning to assess the protection effect of its Capture and Contain (C&C) platform against the recently emerged variant. The study is planned to begin in Q1 2022.

For further details see:

Medigus company Polyrizon to test its product candidate against Omicron variant